Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Roche's CEO Warns Russia-Ukraine War Causing Problems For Multiple Sclerosis Trials

  • The development of Roche Holdings AG's (OTC:RHHBY) multiple sclerosis candidate fenebrutinib is negatively impacted by Russia's ongoing invasion of Ukraine.
  • Reuters reported that between 20% and 30% of clinical trial participants for the phase 3 drug are in the two countries.
  • "Both Ukraine and Russia historically have been very important contributors to clinical trials for patients with neurological disorders such as multiple sclerosis," Roche (RHHBY) CEO Bill Anderson said.
  • Related: COVID-19 Tests Boost Roche's Q1 Sales, Reaffirms FY22 Outlook.
  • As a result, Roche (RHHBY) is recruiting for sites in countries it already has ongoing trials and is opening sites in new countries.
  • For a phase 3b trial testing a higher dose of Ocrevus and studies for experimental oral BTK inhibitor fenebrutinib for MS, Roche had to open additional sites in other countries, Anderson said.
  • While the war has massively disrupted trials in Ukraine, no more new trial participants will be recruited in Russia as part of Roche's response to Moscow's invasion.
  • Also See: EMA's Advisory Committee Recommends Approval For Roche's Two Cancer Drugs.
  • Price Action: RHHBY shares closed up 0.50% at $48.12 on Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.